Colchicine has been reported to destroy ganglion cells (GCs) in the retina of hatchling chicks. We tested whether colchicine influences normal ocular growth and form-deprivation myopia, and whether it affects cells other than GCs. Colchicine greatly increased axial length, equatorial diameter, eye weight, and myopic refractive error, while reducing corneal curvature. Colchicine caused DNA fragmentation in many GCs and some amacrine cells and photoreceptors, ultimately leading to the destruction of most GCs and particular sub-sets of amacrine cells. Colchicine-induced ocular growth may result from the destruction of amacrine cells that normally suppress ocular growth, and corneal flattening may result from the destruction of GCs whose central pathway normally plays a role in shaping the cornea.
Introduction
The shape and size of the eye are crucial to the quality of vision. Emmetropia is achieved when the distance between the retina and the lens is matched to the combined refractive power of the lens and cornea so that distant images are focussed upon the retina with accommodation relaxed. If the focal plane of an image falls in front of the retina the eye is myopic (nearsighted), whereas if the focal plane is behind the retina the eye is hyperopic (far-sighted). Early in life, growth of the eye is regulated precisely so that emmetropia is achieved. The process of emmetropization can be perturbed by depriving the eye of patterned images, which results in elongation of the vitreous chamber and myopia (Wallman, 1993) . The paradigm of form-deprivation myopia (FDM), commonly studied in chicks, has provided ample evidence that visual experience is required to properly guide ocular growth and that this regulation of growth is mediated by retinal activity (Wallman, Gottlieb, Rajaram & Fugate-Wentzek, 1987; Troilo, Gottlieb & Wallman, 1987) .
One question that has been addressed by researchers is whether accommodation and retinal connections to the brain are required for emmetropization. Disabling of accommodative mechanisms and interruption of retinal connections to the brain by optic nerve section, intravitreal application of tetrodotoxin, lesions to the nucleus of Edinger-Westphal, removal of the ciliary ganglion, or severing of the ciliary nerves have little or no effect on emmetropization or FDM (Wallman, Rosenthal, Adams & Romagnona, 1981; Troilo, Gottlieb & Wallman, 1987; Schaeffel, Glasser & Howland, 1988; Schaeffel, Troilo, Wallman & Howland, 1990; Troilo, 1990; Troilo & Wallman, 1991; Wildsoet & Howland, 1991; McBrien, Moghaddam, Cottriall, Leech & Cornell, 1995) . These findings suggest that the mechanisms of visual guidance of ocular growth are intrinsic to the eye and do not require active accomodation or communication with higher visual centers.
The purpose of this study was to explore another model for removal of retinal input to the brain, and thereby to test independently the hypothesis that retinal connections to the brain are required to modulate ocular growth. Colchicine has been reported to destroy most retinal ganglion cells, while sparing intrinsic retinal neurons (Morgan, 1981) . Therefore, we injected colchicine into the eyes of newly hatched chicks, measured their refractive state and ocular dimensions 2 weeks after treatment, tested whether they could respond to form-deprivation, and characterized damage caused by colchicine using a variety of cytochemical markers. Surprisingly, we found that colchicine caused large increases in the size of eyes, comparable to those caused by form-deprivation, accompanied by corneal flattening. In addition, colchicine not only destroyed ganglion cells but also amacrine cells, including some that have been implicated in the visual regulation of ocular growth. We conclude that colchicine not only affects retinal ganglion cells, but also damages or destroys specific subsets of retinal amacrine cells. It is likely that some of the lesioned amacrine cells are normally responsible for the visual control of vitreal chamber elongation, whereas the ablated ganglion cells control corneal shape via central and peripheral neural pathways.
Material and methods

Animals
Newly hatched male leghorn chickens (Gallus gallus domesticus) were obtained from Lillydale Hatchery (Linden, Alberta) and kept on a cycle of 12 h light, 12 h dark (lights on at 07:00 h). Illumination was provided by 100 W incandescent light bulbs, resulting in irradiance levels 50.8 cpd/m 2 , depending on the direction of gaze. Prior to experimentation, chicks were held for 1 week in a stainless steel brooder, at about 25 o C. Chicks received water and Purina™ chick starter ad libitum.
Intraocular injections
Chicks were anesthetized with 1.5% halothane in 50% N 2 O and 50% O 2 prior to injection. Injections were made into the vitreous chamber using a 25-ml Hamilton syringe with a 26 gauge needle. Penetration of the needle was consistently made into the dorsal quadrant of the eye. Shortly after the chicks were hatched, the right eye (control) was injected with 20 ml of vehicle (sterile saline) and the left eye (treated) was injected with 20 ml of sterile saline or 20 ml of 25 mM (0.5 nmol or 0.2 mg) colchicine (Research Biochemicals Internationl, Natick, MA). Assuming that the volume of liquid-vitreous within an eye was 150 ml, the initial maximum concentration of colchicine presented to the retina was about 3 mM. One, 3 and 7 days later, pupillary responses were tested by shining a flashlight over the dark-adapted eye of the chick. Seven days after treatment, eyes were either covered with a translucent goggle or left open. At 7 days (i.e. before form-deprivation) and 14 days of age (i.e. after formdeprivation), eyes were refracted using a streak retinoscope and trial lenses without cycloplegia or anesthesia. At 14 days of age chicks were killed by chloroform inhalation, eyes removed from the orbit, and most of the attached connective tissues and muscles trimmed away. Eyes were weighed (to the nearest milligram) using a Mettler PL200 digital balance, and the equatorial diameter (at the most narrow part of the eye) and axial length (at the apex of the cornea to the base of the posterior eye) were measured using digital calipers.
Fixation and sectioning
Enucleated eyes were hemisected equatorially and the gel vitreous removed from the posterior eye cup. Eye cups were fixed for 30 min at 20 o C in 4% paraformaldehyde plus 3% sucrose in 0.1 M phosphate buffer, pH 7.4. Some samples were fixed for 24 h at 4 o C, since these conditions were better for immunolabelling with antisera to GAD-65, GABA or serotonin. Fixed samples were washed three times in PBS (phosphate-buffered saline; 0.05 M phosphate buffer, 195 mM NaCl, pH 7.4), cryoprotected in PBS plus 30% sucrose, soaked in embedding medium (OCT-compound; Tissue-Tek) for 10 min, and freeze-mounted onto aluminum sectioning blocks. Vertical sections nominally 12-14 mm thick were cut consistently from the posterior pole of the eye in the nasotemporal plane, near the dorsal portion of the pecten, and thawmounted onto gelatin-coated glass slides. Sections from control and treated eyes from the same individual were placed consecutively on each slide to ensure equal exposures to reagents. Sections were air-dried, ringed with rubber cement, and stored at − 20 o C until use.
Immunocytochemistry
Sections were washed three times in PBS, covered with primary antibody solution (Table 1; 150 ml of antiserum diluted in PBS plus 5% normal goat serum, 0.3% Triton X-100, and 0.01% NaN 3 ), and incubated for about 24 h at 20 o C in a humidified chamber. The slides were washed three times in PBS, covered with secondary antibody solution (150 ml of 1:1500 Cy3-conjugated goat-anti-rabbit IgG or mouse IgG, Amersham), and incubated for at least 2 h at 20 o C in a humidified chamber. Finally, samples were washed three times in PBS, rubber cement removed from the slides, and coverslips mounted on 4:1 (v/v) glycerol to water for observation under an epifluorescence microscope using a rhodamine filter combination. Photographs were taken on T-Max 400 film (Kodak) and negatives developed in T-Max Developer (Kodak) as per the manufacturer's instructions. 
Histology
Slides were warmed to 20 o C, washed three times in PBS, and incubated under 200 ml 0.1% (w/v) toluidine blue plus 0.2% (w/v) Na 2 B 4 O 7 in dH 2 O at pH 11.4 for about 2 min. The stain was drained away, slides washed three times in PBS, and mounted, as described above, for microscopy in transmitted white light.
Labelling of fragmented DNA
Retinal sections were obtained as described above from chicks 1, 3, 5 and 7 days after colchicine-treatment. Slides were warmed to 20 o C and washed once in PBS, followed by one wash in PBS plus 0.3% Triton X-100, and two more washes in normal PBS. Sections were then covered with 150 ml of incubation medium (0.5 nmol Cy3-conjugated dCTP, 20 units of 3%-terminal deoxynucleotidyl transferase (Amersham), 100 mM sodium cacodylate, 2 mM CoCl 2 , and 0.25 mM i-mercaptoethanol, in distilled water at pH 7.2) and incubated for 1 h in a humidified chamber at 37 o C. Sections were then washed three times in PBS, mounted in 4:1 (v/v) glycerol to water, and coverslips added for observation by epifluorescence using a rhodamine filter combination.
Measurements of corneal cur6ature
Photographs were made of enucleated eyes viewed from the side. The negatives of these photographs were digitized to a resolution of 20 pixels per mm. Using Adobe Photoshop 4.0™, a rectangular area was blocked out, with one corner originating at the apex of the cornea while the opposing corner was set at the base of the cornea. The number of pixels in the height and width of the rectangle was then determined, and a height to width ratio calculated as a function representative of corneal curvature.
Measurements, cell counts, and statistical analyses
Errors were calculated as the standard deviation of each sample which was comprised of at least six individuals per group. To assess the differences between data from treated and control eyes, we used a paired two-tailed Student t-test. To assess the differences between eyes from multiple different treatments, we used a two-way ANOVA (In Stat© for MacIntosh). Percentage IPL depth was calculated as the distance from the border between the inner plexiform layer (IPL) and inner nuclear layer (INL), divided by the total IPL thickness, multiplied by 100. All thickness measurements were made from photomicrographs of central retina, while all cell counts of at least 50 cells per individual on at least four different sections were made under the microscope.
Results
Pupillary responses
One day after treatment with colchicine, all chicks (n=32) had pupillary responses, although the responses in treated eyes were slightly reduced. Three and 7 days after treatment, eyes injected with saline had strong pupillary constriction when exposed to bright light, while there was no response in colchicine-treated eyes. Furthermore, by 3 days after treatment chicks were blind in their treated eye, as they did not respond to an approaching hand. All chicks were still able to feed normally.
Changes in gross retinal morphology
Histological and immunocytochemical examinations were made only 14 days after treatment, when the colchicine-induced lesion should have been stabilized (Morgan, 1981) . Colchicine caused significant losses of thickness from several retinal layers, particularly the optic fibre layer (OFL) (28.7 96.2% of the control; mean 9 S.D.; n=8) and IPL (55.5 98.3% of the control). The thickness of the INL was also slightly reduced to 83.198.6% of the control. Colchicine caused an obvious loss of cells and thickness from the ganglion cell layer (GCL ; Fig. 1) ; the majority of the cells remaining were assumed to be displaced amacrine cells (Morgan, 1981) . The photoreceptor layer and retinal pigmented epithelium (RPE) appeared dysplastic, thin or discontinuous in some parts, while appearing thicker in other regions (Fig. 1). 
Effects of colchicine upon immunohistologically distinct populations of retinal neurons
Colchicine caused no detectable loss in labelling intensity or distribution of amacrine cells immunoreactive for GAD-65, GABA A receptor, serotonin, parvalbumin, or PKC, except for the compression of neurites within the thinned IPL. Colchicine had no apparent effect upon bipolar cells labelled with monoclonal antibody M3 or antiserum to PKC, or upon nerve fibers in the choroid that were immunoreactive for NAA, ChAT, TH or VIP (results not shown).
Enkephalin
Antiserum to enkephalin (ENK) labelled many cells having somata near the middle of the INL, and dendrites in several distinct sublaminae of the IPL (Fig.  2a) . These cells are the enkephalin-neurotensin-somatostatin-like immunoreactive (ENSLI) amacrine cells which have been described previously in avian retina (Brecha, Karten & Laverack, 1979; Watt, Li & Lam, 1985; Morgan, Wellard & Boelen, 1994; Watt & Florack, 1994) . After exposure to colchicine there was a substantial loss of ENK-immunoreactive amacrine cells (Fig. 2a) , nearly half of which (45.19 13.8%; n=6) perished after 14 days. The cells that survived appeared normal, lacking noticeable swelling of their somata or degeneration of terminal arbors (Fig. 2a) .
Choline acetyltransferase
Antiserum to choline acetyltransferase (ChAT) labelled many orthotopic and displaced amacrine cells, as well as two prominent strata in the IPL (Fig. 2b) , exactly as described previously (Millar, Ishimoto, Chubb, Epstein, Johnson & Morgan, 1987) . Subtypes of cholinergic amacrine cells included: type-I cells, with somata in the proximal INL and neurites in sublamina 2 of the IPL; type-II cells, with somata in the GCL and neurites in sublamina 4 of the IPL; and type-III cells, with somata near the middle of the INL and neurites diffusely distributed in sublaminae 1 and 3-5 of the IPL. As reported elsewhere, about half of the type-III cells are ENSLI cells (Fischer, Poon, Seltner & Stell, 1998) . Colchicine had no apparent effect upon type-I and type-II cholinergic amacrine cells, while inducing some loss of type-III cells (Fig. 2b) . This was foreshadowed by the results of ENK-immunolabelling, in which many type-III/ENSLI cells were destroyed by colchicine.
Tyrosine hydroxylase
Antiserum to tyrosine hydroxylase (TH) labelled sparsely distributed cell bodies with neurites in three different strata in the IPL, at 0-10, 35, and 75% depth (Fig. 2c) , exactly as described previously (Su & Watt, 1987) . Only about 10% (10.99 6.5%; n=6) of TH-immunoreactive amacrine cells survived exposure to colchicine, and consequently there were massive losses of TH-positive neurites from the IPL; this loss of TH-immunoreactive cells was uniform across the entire retina (Fig. 2c) . 
Vasoacti6e intestinal polypeptide
Antiserum to vasoactive intestinal polypeptide (VIP) labelled puncta in the perinuclear cytoplasm of many cell bodies near the border of the INL and IPL, in addition to sparsely distributed neurites at 0-10, 35, and 70% IPL depth, as described previously ( Fig. 2d ; Brecha, 1983; Seltner & Stell, 1995) . Colchicine caused a substantial loss of VIP-containing cell bodies in the INL and neurites in the IPL (Fig. 2d) .
Glucagon
Antiserum to glucagon labelled amacrine cells having somata at the IPL/INL border, one densely innervated stratum at 0-10% IPL depth, and one sparsely innervated stratum at 35% IPL depth (Fig. 2e) , as described previously (Kiyama, Katayama-Kumoi, Kimmel, Steinbusch, Powell, Smith & Tohyama, 1985) . More than 90% (90.99 1.0%; n=6) of glucagon-immunoreactive amacrine cells were destroyed by colchicine, leaving very few glucagon-containing neurites in the IPL; this loss of glucagon-immunoreactive cells was uniform across the entire retina (Fig. 2e). 
Calretinin
Antiserum to calretinin labelled most cells in the GCL, amacrine cells, and horizontal cells, as well as a subset of bipolar cells with somata located towards the middle of the INL (Fig. 2f) . Both plexiform layers and the OFL were filled with dendrites and/or axons that were immunoreactive for calretinin. Calretinin-immunoreactivity could be distinguished in at least 12 strata within the IPL (Fig. 2f ). This distribution of calretinin is consistent with previous reports (Ellis, Richards & Rogers, 1991; Rogers, Khan & Ellis, 1989; Rogers, 1989) . Two weeks after exposure to colchicine, little or no calretinin immunoreactivity remained in the GCL and OFL (Fig. 2f) . This suggests that the type-II cholinergic cells displaced to the GCL, which were unaffected by colchicine, are not immunoreactive for calretinin. Colchicine had little or no effect upon calretinin-immunoreactive horizontal, bipolar, and amacrine cells. Furthermore, there appeared to be little change in the distribution of calretininimmunoreactivity in the IPL and OPL, except for the compression of strata in the thinned IPL.
Neurofilament-associated antigen (NAA)
Antiserum to neurofilament-associated antigen (NAA) robustly labelled the axons of ganglion cells in the OFL and of displaced ganglion cells or efferent target cells at the INL/IPL border (Fig. 2g) . In control retinas, all ganglion cells were only weakly immunoreactive for NAA (results not shown). Colchicine caused a massive loss of NAA-immunoreactivity from the OFL and significant depletion of NAA-immunoreactive fibres at the INL/IPL border (Fig. 2g) . The few ganglion cells that survived exposure to colchicine became hyperimmunoreactive for NAA and often appeared swollen and abnormal (Fig. 2g) .
Transforming growth factor-i2 (TGF-i2)
Antiserum to transforming growth factor-i2 (TGFi2) labelled sparsely distributed amacrine cells, with somata located near the border of the IPL and INL, and most cells in the GCL (Fig. 2h) , as observed previously (Gudgeon, Fischer & Stell, 1998) . Colchicine had no effect upon TGF-i2-immunoreactive amacrine cells, but abolished most TGF-i2-immunoreactivity in the GCL (Fig. 2h) . Surviving ganglion cells became hyperimmunoreactive for TGF-i2 and often appeared swollen and abnormal (Fig. 2h) .
Colchicine-induced DNA fragmentation
Twenty-four hours after exposure to colchicine there was no detectable DNA fragmentation in treated retinas. However, 3 days after treatment the nuclei of many amacrine cells were labelled for fragmented DNA, while only a few nuclei of photoreceptors and ganglion cells were labelled (Fig. 3b) . Five days after treatment, fragmented DNA was detected in the nuclei of many ganglion cells and a few amacrine cells, but was no longer present in the nuclei of photoreceptors (Fig. 3c) . Seven days after treatment, fragmented DNA was no longer detected in any retinal cells (results not shown).
Ocular growth in colchicine-treated eyes
Fourteen days after treatment with colchicine, eyes had grown excessively and become myopic. In comparison to control eyes, the axial length, equatorial diameter, weight, and negative refractive error were significantly (P B0.0001) greater in treated eyes (Fig.  4) . On average, colchicine-treated eyes were 10.29 2.9% longer, 5.0 91.9% wider, and weighed 20.6 9 4.9% more than contralateral control eyes. These increases in eye size were not significantly different from the increases caused by 7 days of form-deprivation of salineinjected control eyes (Fig. 4) . However, the amount of myopia that resulted from colchicine treatment was significantly (P= 0.0006) less than that caused by formdeprivation. Furthermore, form-deprivation did not further increase eye size or refractive error caused by colchicine (Fig. 4) . Colchicine also caused significant (P= 0.0001; n= 7) flattening of the cornea (Fig. 5) . The height to width ratio of corneas from saline-injected eyes was 0.64590.056 (n =7), while that of corneas from colchicine-treated eyes was 0.4949 0.044 (n= 7). The height of treated corneas was 39.0 98.3% less than that of controls.
Discussion
Colchicine-induced ocular enlargement
Colchicine-treated eyes received normal visual stimuli, which are required for normal growth of the eye, but were unable to emmetropize. Therefore, among the damage elicited by colchicine was the disruption of pathways that promote emmetropization. Colchicine also resulted in the activation of growth-promoting pathways or the destruction of growth-suppressing pathways, thereby allowing ocular growth to run unchecked or by default. These changes in ocular growth may have been caused by colchicine-induced damage to the RPE, photoreceptors, ganglion cells, and/or subsets of amacrine cells, or by undetected damage to ocular tissues.
Colchicine-treated retinas were unable to send the brain normal information regarding the visual environment, because of the destruction of most ganglion cells.
It is unlikely that this loss of ganglion cells caused excessive growth or prevented emmetropization, as optic nerve sectioning also causes destruction of most ganglion cells but has little effect upon normal ocular growth or FDM (McBrien, Moghaddam, Cottriall, Leech & Cornell, 1995; Troilo, Gottlieb & Wallman, 1987; Wildsoet & Pettigrew, 1988) . In fact, lesioning of the optic nerve results in smaller, hyperopic eyes (Troilo, Gottlieb & Wallman, 1987) , although it is not clear whether this is caused by loss of ganglion cell input to the brain or damage to intrinsic retinal circuits due to surgery.
Colchicine also damaged or destroyed some photoreceptors. It is unlikely that photoreceptors participate directly in the visual modulation of ocular growth, although damage to photoreceptors that activate preferentially a critical subset of retinal pathways might in principle disrupt emmetropization. Furthermore, the destruction of many photoreceptors with tunicamycin does not affect normal eye growth or the progression of FDM (Ehrlich, Sattayasai, Zappia & Barrington, 1990) . The destruction of photoreceptors and the RPE with formoguanamine also does not affect normal eye growth, but does prevent FDM (Oishi & Lauber, 1988) . Therefore, it is unlikely that colchicine-induced damage to photoreceptors caused excessive ocular growth or the inability of treated eyes to emmetropize.
The accelerated ocular growth caused by colchicine may have resulted from the destruction of retinal amacrine cells. It is possible that the normal suppressive control of ocular growth requires the activity of amacrine cells that are affected by colchicine, including those that contain VIP, enkephalin and ChAT, TH or glucagon, or other amacrine cells for which we did not probe. Pharmacological studies have implicated several subsets of amacrine cells in the progression of FDM, including those that produce dopamine (Stone, Lin, Laties & Iuvone, 1989) , VIP (Stone, Laties, Raviola & Weisel, 1988; Seltner & Stell, 1995) , ENK (Seltner, Rohrer, Grant & Stell, 1997) , and acetylcholine (Stone, Lin & Laties, 1991; McBrien, Moghaddam & Reeder, 1993; . These studies have suggested that retinal cells that release VIP, ENK or acetylcholine promote ocular growth during formdeprivation, while cells that release dopamine suppress growth. However, in the quisqualate-treated retina, cells containing VIP, ENK or acetylcholine are completely destroyed, yet these eyes remain emmetropic and are capable of responding to form-deprivation, thereby suggesting that these cells do not contribute to visually guided ocular growth (Fischer, Poon, Seltner & Stell, 1998; Fischer, Miethke, Morgan & Stell, 1998) . In contrast, glucagon and TH-immunoreactive amacrine cells are relatively unaffected by quisqualate (Fischer, Poon, Seltner & Stell, 1998) , but are eliminated from colchicine-treated retinas (present study). There is no evidence that glucagon-immunoreactive amacrine cells modulate ocular growth. The evidence for a role of dopamine and TH-immunoreactive cells in growth-regulation and FDM is mixed, but the concurrent destruction of TH cells and induction of ocular enlargement by colchicine is consistent with other evidence favoring such a role (Stone, Lin, Laties & Iuvone, 1989; Rohrer, Spira & Stell, 1993) . Alternatively, colchicine may have destroyed or influenced the activity of cells in the choroid or sclera that normally suppress ocular growth. However, it is counter-intuitive to expect that colchicine-induced destruction or suppression of normal cellular activities, such as mitosis or secretion of synthesized products, could result in excessive ocular growth. It also seems unlikely that a single dose of colchicine could elicit an effect over the 2-week observation period used in our experiments unless there was a permanent removal of cells without any replacement.
Form-deprivation did not further enhance the negative refractive error or the increased size of colchicinetreated eyes. It is possible that the mechanisms that promote ocular growth were 'saturated' in both formdeprived and colchicine-treated eyes, so that maximum rates of growth occurred in both conditions. If maximum rates of growth were achieved in both form-deprived and colchicine-treated eyes, then eyes should have been equally large for both treatments, and formdeprivation of colchicine-treated eyes should not have resulted in further enhancement of eye size. Indeed, we found that the size of eyes that were form-deprived, colchicine-treated, and colchicine-treated and form-deprived were nearly equivalent. This suggests that colchicine and form-deprivation activate the same mechanism that enhances ocular growth. Alternatively, growth-promoting mechanisms may not have been saturated, and colchicine may have destroyed the retinal circuitry responsible for form-deprivation-induced growth, thereby rendering the treated eyes unresponsive to form-deprivation.
Colchicine-induced corneal flattening
Colchicine caused a pronounced flattening of the cornea. This accounted at least in part for the smaller degree of myopia in colchicine-treated open eyes than in saline-treated form-deprived eyes, as the ocular dimensions of these eyes were not significantly different and in themselves should have produced similar refractive errors. Flattening of the cornea would result in reduced refractive power, thereby decreasing the refractive error of these enlarged eyes. It is also possible that choroidal thickening (Wallman, Wildsoet, Xu, Gottlieb, Nickla, Marran, Krebs & Christensen, 1995; could have decreased refractive error of colchicine-treated eyes, but this possibility was not tested in these experiments.
Corneal flattening may have resulted from the colchicine-induced loss of ganglion cells. Flattening of the cornea was observed by Troilo & Wallman (1991) after optic nerve sectioning, and by McBrien, Moghaddam, Cottriall, Leech & Cornell (1995) after chronic administration of tetrodotoxin. Although colchicine, tetrodotoxin, and optic nerve lesioning all elicit different effects and may perturb different functions within the eye, they share suppression or abolition of ganglion cell activity and transmission to the brain. Therefore, we propose that corneal growth is regulated by activity in one or more classes of retinal ganglion cell, presumably through some visual center(s) in the brain and outflow via the cilary ganglion and nerves.
Colchicine-induced destruction of retinal cells
The mechanisms underlying the destruction of retinal cells by colchicine remain uncertain. Fragmented DNA was detected in both amacrine and ganglion cells, suggesting that these cells became apoptotic after exposure to colchicine. Colchicine causes the disassembly of microtubules, and thereby interferes with many cellular functions. One function disrupted by colchicine is axonal transport (Hanson & Edström, 1978) , and ganglion cells might be expected to perish because both anterograde and retrograde transport (e.g. of trophic factors) were disabled. The reduction in effect of colchicine in the eyes of older chicks (Morgan, 1981) , might reflect a reduced trophic dependency. However, in the chick, natural death of retinal ganglion cells and establishment of retinotectal connections occur before hatching (Rager, 1976; Rager & Rager, 1978; Rager & Oeynehausen, 1979) . Competition for trophic targets would, therefore, be completed long before we observed colchicine-induced cell death. This does not, however, exclude the possibility that these cells have a continued trophic dependency after tectal connections have been established. This in fact is likely, since axotomy usually results in the death of ganglion cells (Bray, Villegas-Perez, Vidal-Sanz, Carter & Aguayo, 1991) .
Colchicine probably prevented the anterograde transport of proteins away from the cell bodies of residual ganglion cells. The accumulation of NAA and TGF-i2-immunoreactivity in some ganglion cells after exposure to colchicine suggests that protein synthesis was unaffected while the transport of synthesized products away from the cell body was disabled. Residual ganglion cells are likely to be non-functional or dysfunctional, as axonal transportation was prevented. The consequent accumulation of TGF-i2-immunoreactivity in ganglion cell bodies implies that TGF-i2 is normally exported out of the retina along axons, or into the IPL in dendrites. It has been argued that the blockade of anterograde transport and subsequent build-up of proteins in cell bodies results in apoptosis and that this is somehow related to the degree of axon myelination and requirements for the exchange of lipid materials between axons and oligodendrocytes (Droz, 1979; Morgan, 1981) .
It remains uncertain why only certain sub-populations of amacrine cells perished after exposure to colchicine. There is no precedent for dependence of intrinsic retinal neurons on cytoplasmic transport of trophic factors. However, there is also no evidence against such dependence and thus we cannot exclude the possiblity that colchicine caused the death of amacrine cells by depriving them of retrogradedly transported trophic factors. All types of amacrine cells that were affected by colchicine, in particular the strongly affected TH and glucagon-immunoreactive cells, had broad dendritic arbors. It is possible that the wide dendritic arbors and consequently increased requirements for anterograde and retrograde transport rendered these amacrine cells more susceptible to colchicine-induced cell death. For example, colchicine-induced cytoskeletal alterations in rat cerebellar granule cells have been postulated to directly initiate apoptosis (Bonofoco, Ceccatelli, Manzo & Nicotera, 1995) .
Summary and conclusions
Colchicine destroyed most ganglion cells, as well as subtypes of amacrine cells including those thought to participate in visual guidance of ocular growth. Colchicine also damaged the RPE and photoreceptors. As a result of the damage caused by colchicine, eyes were unable to emmetropize, grew excessively, became myopic, and had flattened corneas. We propose that colchicine-induced elongation of the vitreous chamber results from the destruction of one or more subsets of amacrine cells that normally suppress growth in response to visual stimuli, and that colchicine-induced corneal flattening results from the destruction of one or more subsets of ganglion cells that normally promote proper corneal shape.
